Latest & greatest articles for insomnia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insomnia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insomnia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insomnia

1. Treatment for Insomnia and Disrupted Sleep Behavior in Children and Adolescents with Autism Spectrum Disorder

Treatment for Insomnia and Disrupted Sleep Behavior in Children and Adolescents with Autism Spectrum Disorder 1 1 Practice guideline: Treatment for insomnia and disrupted sleep behavior in children and 2 adolescents with autism spectrum disorder 3 4 Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the 5 American Academy of Neurology 6 7 Ashura Williams Buckley, MD, 1 Deborah Hirtz, MD, 2 Maryam Oskoui, MD, 3 Melissa J. 8 Armstrong, MD, MSc, 4 Anshu Batra (...) and adolescents 15 may respond to cognitive behavioral therapy (CBT) adapted from adult paradigms. 22, 23 These 16 interventions are short-term, multicomponent, goal-oriented psychotherapeutic treatments aiming 17 to modify thinking patterns and behaviors that perpetuate insomnia (e.g., irregular sleep–wake 18 schedules, poor sleep hygiene, and maladaptive habits). 19 20 This guideline addresses the following question: 21 17 In children and adolescents with ASD, which pharmacologic, behavioral, and CAM

2020 American Academy of Neurology

2. Lemborexant (Dayvigo) - insomnia

Lemborexant (Dayvigo) - insomnia Drug Approval Package: DAYVIGO DAYVIGO " /> U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: DAYVIGO Company: Eisai Inc. Application Number: 212028 Approval Date: 12/20/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created

2020 FDA - Drug Approval Package

3. Placebo effect of acupuncture on insomnia: a systematic review and meta-analysis

Placebo effect of acupuncture on insomnia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2020 PROSPERO

4. Insomnia, sleep, night working shifts and health outcomes: an umbrella review of meta-analyses of cohort and case-control studies

Insomnia, sleep, night working shifts and health outcomes: an umbrella review of meta-analyses of cohort and case-control studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2020 PROSPERO

5. Global prevalence of insomnia and poor sleep in chronic kidney disease: a systematic review and meta-analysis

Global prevalence of insomnia and poor sleep in chronic kidney disease: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

6. Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Melatonin for Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines Last updated: February 22, 2019 Project Number: RC1073-000 Product Line: Research (...) Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of melatonin for the treatment of insomnia in adults? What is the cost-effectiveness of melatonin for the treatment of insomnia in adults? What are the evidence-based guidelines regarding the use of melatonin for the treatment of insomnia in adults? Key Message Evidence of limited quality from four systematic reviews and two randomized controlled trials suggested modest favourable

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Melatonin (Slenyto) - Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome

Melatonin (Slenyto) - Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome 1 Published 9 September 2019 1 SMC2168 melatonin 1mg and 5mg prolonged-release tablets (Slenyto®) Flynn Pharma Ltd 9 August 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised (...) as follows: ADVICE: following a full submission melatonin prolonged-release (Slenyto ® ) is not recommended for use within NHSScotland. Indication under review: Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. Melatonin prolonged-release (Slenyto ® ), compared with placebo, increased total sleep time and sleep onset latency in children aged 2 to 17.5 years with sleep

2019 Scottish Medicines Consortium

8. British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update

British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update Original Paper British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders SJ Wilson 1 , DJ Nutt 2 , C Alford 3 , SV Argyropoulos 4 , DS Baldwin 5 , AN Bateson 6 , TC Britton 7 , C Crowe 8 , D-J Dijk 9 , CA Espie 10 , P Gringras 11 , G Hajak 12 , C (...) , whichrepresents the views of all participants although the authors take final responsibility for the document. Keywords Sleep, insomnia, parasomnia, circadian rhythm disorder, consensus, treatment Introduction Sleepdisordersarecommoninthegeneralpopulationandeven more so in clinical practice, yet are relatively poorly under- stood by doctors and other health care practitioners. These BritishAssociationforPsychopharmacology(BAP)guidelines aredesignedtoaddressthisproblembyprovidinganaccessible yetup

2019 British Association for Psychopharmacology

9. Nurse-led cognitive behavioural group treatment intervention for insomnia successfully reduces daytime symptomatology. (Abstract)

Nurse-led cognitive behavioural group treatment intervention for insomnia successfully reduces daytime symptomatology. 31147344 2019 06 26 2019 06 26 1468-9618 22 3 2019 07 Evidence-based nursing Evid Based Nurs Nurse-led cognitive behavioural group treatment intervention for insomnia successfully reduces daytime symptomatology. 79 10.1136/ebnurs-2018-102975 Scott Lauren L 0000-0001-9526-2385 Faculty of Nursing, The University of Toronto, Toronto, Ontario, Canada. Bawden Jessica J Faculty

2019 Evidence-Based Nursing Controlled trial quality: uncertain

10. Belsomra (Suvorexant) - for the treatment of insomnia

Belsomra (Suvorexant) - for the treatment of insomnia Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1

2019 Health Canada - Drug and Health Product Register

11. Insomnia

Insomnia © 2019 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 Insomnia Guideline Guideline Summary 2 Background 2 Assessment and Diagnosis 3 Monitoring 4 Treatment Foundations Normal sleep pattern changes in the elderly 5 Step-wise approach to insomnia treatment 5 Behavioral treatment 6 Complementary/alternative therapy 7 Adjunctive pharmacologic treatment if no response to behavioral treatment 8 Recommendations for Special Populations 10 Follow-up 10 Referral 10 Evidence (...) consultation with Women’s Health. Insomnia is a sleep disorder characterized by difficulty falling and/or staying asleep for a month or longer. Individuals with insomnia may have one or more of the following symptoms: • Difficulty falling asleep • Waking up often during the night and having trouble going back to sleep • Waking up too early in the morning • Feeling tired upon waking Acute insomnia is insomnia lasting less than 6 weeks. Chronic insomnia is insomnia occurring at least 3 nights a week for more

2019 Kaiser Permanente Clinical Guidelines

12. Proof of Concept for an Adaptive Treatment Strategy to Prevent Failures in Internet-Delivered CBT: A Single-Blind Randomized Clinical Trial With Insomnia Patients (Abstract)

Proof of Concept for an Adaptive Treatment Strategy to Prevent Failures in Internet-Delivered CBT: A Single-Blind Randomized Clinical Trial With Insomnia Patients This study aimed to demonstrate proof of concept for an adaptive treatment strategy in Internet-delivered cognitive-behavioral therapy (ICBT), where risk of treatment failure is assessed early in treatment and treatment for at-risk patients is adapted to prevent treatment failure.A semiautomated algorithm assessed risk of treatment (...) failure early in treatment in 251 patients undergoing ICBT for insomnia with therapist guidance. At-risk patients were randomly assigned to continue standard ICBT or to receive adapted ICBT. The primary outcome was self-rated insomnia symptoms using the Insomnia Severity Index in a linear mixed-effects model. The main secondary outcome was treatment failure (having neither responded nor remitted at the posttreatment assessment).A total of 102 patients were classified as at risk and randomly assigned

2019 EvidenceUpdates

13. Intervention for insomnia during pregnancy: a systematic review

Intervention for insomnia during pregnancy: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2019 PROSPERO

14. Effectiveness and safety of fire-needle moxibustion on insomnia: protocol for a systematic review

Effectiveness and safety of fire-needle moxibustion on insomnia: protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2019 PROSPERO

15. Effectiveness and safety of warming-needle moxibustion combined with auricular point sticking therapy on insomnia: protocol for a systematic review

Effectiveness and safety of warming-needle moxibustion combined with auricular point sticking therapy on insomnia: protocol for a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

16. Auriculotherapy for sleep quality in people with primary insomnia: a systematic review and meta-analysis

Auriculotherapy for sleep quality in people with primary insomnia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2019 PROSPERO

17. In clinical and community-based samples (P), do insomnia and/or sleep disturbances (E) predict child and youth depression (O) compared to typical sleep (C)? A systematic review and meta-analysis

In clinical and community-based samples (P), do insomnia and/or sleep disturbances (E) predict child and youth depression (O) compared to typical sleep (C)? A systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

18. Effectiveness of Traditional Chinese medicine for insomnia in patients with hypertension: a systematic review

Effectiveness of Traditional Chinese medicine for insomnia in patients with hypertension: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

19. Deprescribing of chronic benzodiazepine receptor agonists for insomnia in adults [Cochrane protocol]

Deprescribing of chronic benzodiazepine receptor agonists for insomnia in adults [Cochrane protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

20. Non-invasive brain stimulation to treat insomnia and sleep quality

Non-invasive brain stimulation to treat insomnia and sleep quality Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO